The DNA-damage response (DDR) pathways consist of interconnected components that respond to DNA damage to allow repair and promote cell survival. The DNA repair pathways and downstream cellular responses have diverged in cancer cells compared with normal cells because of genetic alterations that underlie drug resistance, disabled repair and resistance to apoptosis. Consequently, abrogating DDR pathways represents an important mechanism for enhancing the therapeutic index of DNA-damaging anticancer agents. In this review, we discuss the DDR pathways that determine antitumor effects of DNA-damaging agents with a specific focus on treatment outcomes in tumors carrying a defective p53 pathway. Finely tuned survival and death pathways govern the cellular responses downstream of the cytotoxic insults inherent in anticancer treatment. The significance and relative contributions of cellular responses including apoptosis, mitotic catastrophe and senescence are discussed in relation to the web of molecular interactions that affect such outcomes. We propose that promising combinations of DNA-damaging anticancer treatments with DDR-pathway inhibition would be further enhanced by activating downstream apoptotic pathways. The proposed rationale ensures that actual cell death is the preferred outcome of cancer treatment instead of other responses, including reversible cell cycle arrest, autophagy or senescence. Finally, to better measure the contribution of different cellular responses to anticancer treatments, multiplex in vivo assessments of therapy-induced response pathways such as cell death, senescence and mitotic catastrophe is desirable rather than the current reliance on the measurement of a single response pathway such as apoptosis. Oncogene (2010) 29, 6085-6098; doi:10.1038 /onc.2010 ; published online 6 September 2010
Keywords: DNA-damage response; DNA repair; cell cycle checkpoints; cell death; mitotic catastrophe; cellular senescence Introduction DNA-damaging agents are effective and prolong survival of cancer patients (Hurley, 2002) . The optimal therapeutic strategy incorporating these agents is to kill cancer cells while sparing normal tissues. The function of the DNA-damage response (DDR) pathways is to activate multiple downstream processes that delay cell cycle progression (temporary cell cycle arrest), thereby allowing the repair of damaged DNA (Khanna and Jackson, 2001; Helt et al., 2005; Branzei and Foiani, 2008; Powell and Bindra, 2009 ). The therapeutic index of DNA-damaging anticancer agents, defined as the ratio of tumor cure/normal tissue complications (Zhou and Bartek, 2004) , can be enhanced by the inhibition of DNA repair or cell cycle checkpoint pathways. The redundancy of DNA repair pathways in normal cells contrasts with the frequency of disabled DNA repair in cancer cells, which then depend on fewer DNA repair pathways for their survival. Consequently, DDR pathways represent exciting new cancer therapy targets. Here, we discuss DDR pathways that underlie antitumor effects of DNA-damaging agents, with a specific focus on treatment effects in the absence of a functional p53 pathway.
DDR signal transduction
A wide range of DNA lesions elicit the activation of DDR pathways and subsequent cell cycle checkpoints. DDR pathways resemble the signaling paradigm established for growth factors, in which the cognate pathway comprises detection, signal transduction and effector phases. The increasing complexity of signal transduction in response to DNA damage is summarized schematically ( Figure 1 ). The detectors of DNA-damage signaling activate signal transducers by recruiting them to sites of DNA damage and include the Mre11-Rad50-Nbs1 complex and replication protein A-coated singlestranded DNA. The key signal transducers downstream of the detectors are the ataxia telangiectasia-mutated (ATM) and ATM-Rad3-related (ATR) protein kinases.
ATM and ATR belong to a family of conserved phosphoinositide 3 kinase-related kinases that have conserved orthologs in eukaryotes (Abraham, 2001) . ATM and ATR are Ser/Thr-Gln-directed protein kinases with overlapping substrate specificities. Whereas the ATM pathway is active during all phases of the cell cycle in response to double-strand breaks (DSBs), ATR acts primarily in S and G2 phases of the cell cycle in an ATM-dependent manner (Gatei et al., 2003; Jazayeri et al., 2006) . The ATR pathway mainly responds to agents that interfere with the function of DNA replication forks (replication stress), such as ultraviolet light and gemcitabine, although it is now recognized that the ATR pathway can also activate downstream components of the ATM arm following replication fork stalling or ultraviolet treatment (Stiff et al., 2006) . In addition, DNA-alkylating agents can activate both pathways. Although such agents impose stress on progressing replication forks, they can also elicit strand breaks under some circumstances (Zhou and Bartek, 2004) . These studies suggest that these kinases act in somewhat overlapping pathways of DNA-damage signaling. However, they appear to have independent functions in the progression through a normal, unperturbed, cell cycle. Consistent with this, ATR deficiency in mice results in early embryonic lethality associated with the loss of cellular proliferative potential and extensive apoptosis, whereas cells and animals survive quite well without ATM (Barlow et al., 1998; Brown and Baltimore, 2000; de Klein et al., 2000) .
Checkpoint proteins 1 and 2 (Chk1 and Chk2) are key downstream substrates of ATM and ATR (Figure 1 ). Chk1 or Chk2 phosphorylate several downstream substrates necessary for activating the DNA-damage checkpoints and subsequently halting the cell cycle. In addition to the canonical ATM/ATR-Chk2-p53 and ATM/ATR-Chk1 pathways, a role for polo-like kinase 3 (Plk3) in Cdc25 phosphatase regulation during DNA damage is emerging (Myer et al., 2005) . Plk3 has a functional role in a pathway linking ATM, Plk3, Chk2, Cdc25C and Cdc2 in the cellular response to DNA damage and the G2/M checkpoint (Bahassi el et al., 2006) . Furthermore, a rapid response pathway involving ATM, Plk3, Chk2 and Cdc25A regulates the G1/S transition (Hong and Stambrook, 2004; Myer et al., 2005) . More recently, the p38MAPK/MAPKAP-K2 (MK2) complex 
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Figure 1 DNA-damage response pathway. A set of targets lie downstream of ATM and ATR, including DNA repair proteins BRCA1, NBS1, BLM1, cAbl and 53BP1; cell cycle checkpoint proteins Chk1 and Chk2; and S-phase delay effectors FANCD2 and SMC1 (Zhou and Elledge, 2000) . In addition, downstream targets of ATM include p53 and MDM2 (not shown in the figure), which are phosphorylated at Ser-15 and Ser-395, respectively. p53 is also phosphorylated by ATR at Ser-15. Furthermore, p53 is phosphorylated at Ser-20 by ATM-activated Chk2 (Abraham, 2001) . Accumulation (by loss of MDM2 inhibition) and stabilization or activation of p53 (by phospho-Chk2 and phosphor-ATM-mediated phosphorylation) exert p53-dependent G1/S arrest or apoptosis (Abraham, 2001) . Details of p53 functions in the DDR pathway have been reviewed extensively (Ljungman, 2000; Meulmeester and Jochemsen, 2008) .
Targeting DDR pathways to improve cancer treatment F Al-Ejeh et al has been characterized as an additional checkpoint transducer downstream of ATM and ATR (Reinhardt and Yaffe, 2009; Thornton and Rincon, 2009 ). The p38MAPK/MK2 signaling complex is considered to be part of a general stress response pathway that is activated in response to a variety of stimuli including DNA damage. MK2 is suggested to act in a pathway that synergizes with the classical checkpoint effectors Chk1 and Chk2 (Reinhardt and Yaffe, 2009 ) independent of p53 function (Reinhardt et al., 2007) . The effectors lie downstream of signal-transducing molecules and are involved in the inhibition of cell cycle progression, DNA repair activation and maintenance of genome stability. When damage is beyond repair, proteins in the DDR network mediate one of two effector functions: initiation of permanent cell cycle arrest (cellular senescence) or cell death (Zhou and Elledge, 2000; Abraham, 2001; Khanna and Jackson, 2001; Sancar et al., 2004) . Characterizing these two outcomes will have important implications for understanding DDR signaling and improving the efficacy of DNA-damaging agents used in anticancer treatments (Zhou and Bartek, 2004; Bucher and Britten, 2008) . Although Chk1 and Chk2 proteins exhibit comparable cellular activities, Chk1 is important for checkpoint and replication arms of the DDR signaling, whereas Chk2 is more important for DNA-damage-induced apoptosis (Zhou and Bartek, 2004) . However, as 50% of cancers lack functional p53, DDR signaling via the ATM/ATRChk2-p53 pathway is attenuated. Furthermore, while G1 arrest may be initiated independently of p53 (Agami and Bernards, 2000) , it is not maintained owing to the lack of functional p53. Consequently, p53-mutant cancer cells are more resistant to apoptosis and rely on the S-and G2-phase checkpoints to repair DNA damage and promote cell survival (Ashwell and Zabludoff, 2008) .
Targeting the DNA repair pathways Genetic lesions include DNA base damage or base misincorporation, DNA crosslinks and DNA DSBs. These are repaired by (1) direct reversal, (2) base excision repair (BER), (3) nucleotide excision repair, (4) mismatch repair, (5) homologous recombination (HR), (6) non-homologous end joining (NHEJ) and (7) translesion DNA synthesis. Detailed description of these pathways is beyond the scope of this review and the reader is referred to excellent treatises on DNA repair (Friedberg, 2001; Khanna and Jackson, 2001; Sancar et al., 2004; Lieberman, 2008; Khanna and Shiloh, 2009) .
Several inherited chromosome instability syndromes, such as Xeroderma Pigmentosa, are caused by defects in genes involved in the detection, signaling and repair of the damaged DNA. The defective gene products account for increased cellular DNA damage, incorrect repair of DNA damage and cancer susceptibility in these individuals (Harper and Elledge, 2007) . Similar genetic defects have been found in sporadic cancers and likely contribute to the genomic instability that is a hallmark of cancer (Kennedy and D'Andrea, 2006) . To compensate for the loss of specific DNA repair pathways, other DNA repair pathways may be co-opted to enable tumor cells to survive. Activation of alternative repair pathways has been suggested to be responsible for the limited response of tumors to radio-and chemotherapy. Therefore, anticancer treatments may be made more effective if the DNA repair pathways essential for tumor cell survival can be disrupted. Recent clinical findings validate this new approach to drug development. For example, carcinomas with deficient function of the BRCA1, BRCA2 or Fanconi anemia (FA) genes, which are implicated in HR repair of DNA crosslinking agents, such as cisplatin and mitomycin C, rely on other pathways, such as NHEJ or BER to mend certain types of DNA lesions (Kennedy and D'Andrea, 2006; Lieberman, 2008) . Specific inhibitors of DNA-dependent protein kinase (DNA-PK) or poly(ADP-ribose) polymerase (PARP) used to selectively reduce NHEJ and BER activity, respectively, have been shown to be effective as single-agent therapies in HR-defective tumors (O'Connor et al., 2007; Lieberman, 2008) . Other reports describing inhibitors of BER, HR and mismatch repair pathways offer further prospects for targeted cancer therapies (Bentle et al., 2006; Kelley and Fishel, 2008; Lieberman, 2008) . Platinum compounds are the key drugs for the treatment of cancers defective in FA-BRCA pathway; however, recent reports describe that hypersensitivity of FA-deficient cells to crosslinking agents can be suppressed by the inhibition of NHEJ, possibly owing to reactivation of HR (Adamo et al., 2010; Pace et al., 2010) . Whether this can occur in human cancer in clinical situation is an important issue, which needs to be investigated extensively.
BER and the role of PARP inhibitors PARP-1 detects and binds to DNA single-strand breaks where upon it is triggered to transfer ADP-ribose polymers on various chromatin-associated proteins including PARP-1. The branching ADP-ribose polymers provide a scaffold for the assembly of repair proteins and the initiation of the complex repair reaction (Haince et al., 2005) . Chemo-and radiosensitization by PARP inhibition has been the subject of many reviews (Haince et al., 2005; Plummer, 2006; Plummer and Calvert, 2007; Ratnam and Low, 2007; Lord and Ashworth, 2008) . A review of the original research reports indicates that although chemo-and radiotherapy can synergize with PARP inhibitors (PARPi), the assessment of the resulting cellular responses may be limited if clonogenic survival or growth inhibition are chosen as end points (Calabrese et al., 2003 (Calabrese et al., , 2004 Curtin et al., 2004) .
Potentiation of chemotherapy by PARPi was associated with increased and prolonged G2/M arrest that reduced cell proliferation (Miknyoczki et al., 2003) . Radiosensitization by PARPi, assessed by clonogenic survival, was achieved only in rapidly growing tumor cells with a high S-phase content (Noel et al., 2006) . This radiosensitization may result from PARP-mediated Targeting DDR pathways to improve cancer treatment F Al-Ejeh et al inhibition of single-strand break repair at stalled replication forks leading to the creation of DSBs (Haince et al., 2005) . Consequently, up to 1000-fold higher sensitivity of BRCA-deficient (Bryant et al., 2005; Farmer et al., 2005; McCabe et al., 2005 McCabe et al., , 2006 Evers et al., 2008) or FA protein-deficient cells to PARP inhibition seems to depend on the excess of DSBs generated in the presence of compromised HR. Increased G2/M arrest upon PARP inhibition could explain the higher growth inhibition in FA proteindeficient cells . It is worth noting that in studies of PARPi in cells harboring defects in DNA repair, the use of the generic term 'cell death' (Bryant et al., 2005; Farmer et al., 2005; Gallmeier and Kern, 2005; McCabe et al., 2005) to describe loss of clonogenicity does not adequately describe the multiple outcomes of DNA damage, which include temporary cell cycle arrest, permanent cell cycle arrest (senescence), autophagy, mitotic catastrophe, apoptosis or necrosis. Some of these outcomes may be reversible, or abrupt, or gradually evolve toward tumor cell death. More precise characterization of the underlying response mechanisms may enhance opportunities for improving the therapeutic potential of PARPi not only in HR-deficient tumors but also in combination with DNA-damaging treatments for other tumor types. In support of this notion, recent studies have reported interesting mechanistic complications with the use of PARPi. For example, several observations may be expected to limit the efficiency of the PARP inhibition in BRCA1-and BRCA2-deficient tumors as a synthetic lethal approach. Increase in RAD51 Waddell et al., 2009) and HR can rescue growth defects in BRCA1-deficient cells . Furthermore, the depletion of 53BP1 can rescue BRCA1 deficiency by reactivation of ATM-dependent HR pathway (Bouwman et al., 2010; Bunting et al., 2010) . Indeed, a remarkable correlation exists between the absence of 53BP1 and the most aggressive and difficult-to-treat triple-negative breast tumors (Bouwman et al., 2010) . In addition, 53BP1 loss could be a likely mechanism of resistance to PARPi. These findings have implications on targeted therapies for BRCA-mutant cancers (Boulton, 2010; Kass et al., 2010) and suggest that combinational therapies are required for better outcomes.
NHEJ repair and the role of DNA-PK inhibitors Potent inhibitors of DNA-PK, involved in the NHEJ DNA repair pathway, have been characterized in vitro (Leahy et al., 2004; Griffin et al., 2005; Hardcastle et al., 2005) . Kashishian et al. (2003) investigated compounds that enhance the cytotoxicity of physical and chemical agents and induce DSBs, but not other DNA lesions.
Responses to the combination of DNA-PK inhibitors with DNA-damaging agents include reduced clonogenic survival and cellular proliferation, increased DSBs, G2 arrest and subtle increases in the sub-G1 population (indicative of apoptosis) (Willmore et al., 2004 (Willmore et al., , 2008 Shinohara et al., 2005) , regardless of p53 status (Ismail et al., 2004; Zhao et al., 2006) . Recently, Shang et al.
(2010) reported an important role of DNA-PK in preventing mitotic catastrophe in response to DNA damage. Inactivation of DNA-PK increases polyploidy and mitotic catastrophe after irradiation and attenuates Chk2 phosphorylation in an ATM-independent manner (Shang et al., 2010) . Despite the ability of DNA-PK inhibitors to potentiate chemo-and radiotherapy in vitro and in vivo, the underlying factors that regulate the contribution of cell cycle arrest and cell death to the overall loss of clonogenicity remain unclear.
Combinations of DNA-repair inhibitors DSBs generated by the collapse of replication forks after PARP inhibition of single-strand break repair have provided the rationale for clinical trials that target HRdeficient cancers with PARPi as a 'synthetic lethal' approach (Bryant and Helleday, 2006; Lord et al., 2006) . Preliminary analysis of clinical trial data using the BSI-201 PARPi in combination with gemcitabine/carboplatin in metastatic triple-negative (ER, PR and HER2 negative) breast cancer is encouraging. This combination shows significantly improved clinical benefit rate, progression-free survival and overall survival compared with gemcitabine and cisplatin alone (O'Shaughnessy et al., 2009) . Full results of ongoing clinical investigations of this synthetic lethal approach are awaited.
Interestingly, PARP has also been implicated in a slow alternative NHEJ pathway that is separate from the DNA-PK-dependent classical NHEJ (Audebert et al., 2004 (Audebert et al., , 2008 Wang et al., 2005 Wang et al., , 2006 Shrivastav et al., 2008; Terzoudi et al., 2008; Iliakis, 2009; Robert et al., 2009 ). This finding may further justify the use of PARPi in HR-deficient cancers, especially since the alternative NHEJ pathway may be enhanced in G2 (Wu et al., 2008) . However, the predominant and cell cycle phase-independent NHEJ (classical NHEJ) may limit the efficacy of this 'synthetic lethal' monotherapy approach if tumors exploit such mechanism to thwart the effectiveness of the long-term administration of PARPi. Consequently, studies in which PARP and DNA-PK are both inhibited suggest a powerful strategy for tumor radiosensitization (Veuger et al., 2004; Bryant and Helleday, 2006; Mitchell et al., 2009) . To our knowledge, combinations of PARPi and classical NHEJ inhibitors (for example, DNA-PK inhibitors) with conventional chemotherapy and/or radiotherapy as a treatment strategy remain unexplored. DNA-PK inhibitors are being combined with other DDR inhibitors to enhance the therapeutic potential of anticancer agents. For example, combination of the DNA-PK inhibitor NU7441 with the ATM inhibitor KU-55933 (for review of ATM inhibitors refer to Marone et al. (2008) ) showed strong radiosensitization in the breast carcinoma cell line, MCF-7 (Cowell et al., 2005) . In this model, ATM inhibitors may be expected to inhibit both the repair pathways and induction of cell cycle arrest. Interestingly, despite the wild-type p53 status of the MCF-7 cells and the apparent repair defect manifested by persistence of radiation-induced gH2AX foci, the significant growth reduction of irradiated cells induced by inhibition of these enzymes was not accompanied by increase in levels of apoptosis (Cowell et al., 2005 ). An insight into this effect may come from findings that non-apoptotic forms of cell death can contribute to increased radiation-induced lethality (Jonathan et al., 1999; Sato et al., 2000) .
The sheer complexity of the DDR network continues to frustrate our attempts to develop effective anticancer treatments. For example, while it seemed reasonable that inhibition of DNA-PK and the G2 cell cycle checkpoint would have synergistic antitumor effects, Sturgeon et al. (2006) reported that inhibition of DNA-PK reduces the ability of checkpoint inhibitors to abrogate G2 arrest. The authors hypothesized that 'DNA repair inhibition elicits abnormally strong checkpoint signaling that causes essentially irreversible G2 arrest and strongly reduces the ability of checkpoint kinase inhibitors to overcome G2 arrest and radiosensitize cells' (Sturgeon et al., 2006) . Perhaps, this G2 arrest is aided by activation of the alternative NHEJ pathway, thus rendering escape from G2 arrest by inhibitors inefficient.
Taken together, inhibition of DNA repair potentiates chemo/radiotherapy by enhancing signal transduction through ATM and/or ATR pathways to activate the effectors. At present, the mechanisms that determine whether irreparable damage induces permanent cell cycle arrest (senescence) or cell death (apoptosis) both in the presence or absence of functional p53 are not clear. With evasion of apoptosis often described as a hallmark of cancer (Hanahan and Weinberg, 2000) , cell cycle arrest would be the dominant response pathway. As described in the following sections, abrogation of checkpoint kinases has been proposed as an approach to avoid this DDR-induced cell cycle arrest.
Targeting the DNA-damage cell cycle checkpoints DNA-damage checkpoints delay or arrest the cell cycle in order to repair the damaged DNA and promote cell survival, and therefore limit the effectiveness of many DNA-damaging cancer treatments. Given that the majority of cancer cells are deficient in the G1/S DNA-damage checkpoint resulting in reliance on the S and G2 checkpoint for DNA repair and survival compared with normal cells with functioning G1 checkpoint, it is rational to inhibit these checkpoints to enhance the therapeutic index of current anticancer treatments. As the S-phase checkpoint acts to delay rather than arrest the cell cycle, cancer cells with damaged DNA may progress through this checkpoint only to halt at the G2 checkpoint, which is critical for the protection of the cancer cell genome (Bucher and Britten, 2008) . The rationale of pharmacological checkpoint abrogation, specifically of the G2 checkpoint, in anticancer treatment has been a subject of numerous reviews (Tao and Lin, 2006; Bucher and Britten, 2008; Wang et al., 2009 ). Here, we will focus on the role of Chk1 kinase in the regulation of the G2 checkpoint with an emphasis on the outcomes that can be obtained from its abrogation.
Abrogation of the G2 checkpoint prevents cancer cells from repairing DNA damage, forcing them into the M phase prematurely (with damaged DNA) to produce subsequent antiproliferative effects (Morgan et al., 2005; Bucher and Britten, 2008) . The Chk1 inhibitor PF-00477736 (Pfizer, New York, NY, USA) abrogates gemcitabine-induced S-phase arrest and allows cells to progress through the G2 checkpoint (Blasina et al., 2008) . PF-00477736 also inhibits the mitotic spindle checkpoint and the DNA-damage checkpoint induced by docetaxel . Other selective Chk1 inhibitors were also shown to abrogate the S-phase delay induced by topoisomerase inhibitors (Chen et al., 2006; Tse et al., 2007) and to potentiate the cytotoxicity of g-radiation in p53-deficient cells (Chen et al., 2006) . These effects were associated with increased mitotic entry, induction of DSB and apoptosis, as well as marked inhibition of proliferation (Chen et al., 2006; Tse et al., 2007; Blasina et al., 2008; Zhang et al., 2009) . The synergy between replication stress inducers and Chk1 inhibitors was translated into a dose-dependent increase in tumor growth delay in vivo (Tse et al., 2007; Blasina et al., 2008; Zhang et al., 2009) .
A close examination of the published data suggests that apoptosis is not the major outcome of these combination regimens. The extent of apoptosis did not exceed 20% in the combination of PF-00477736 with gemcitabine (Blasina et al., 2008) and was less than 30% with docetaxel . The proportion of apoptotic cells increased from o5% with single treatments to 30% with the combination of the Chk1 inhibitor CHIR-124 and SN-38 (the active metabolite of irinotecan) (Tse et al., 2007) . In summary, the documented responses to Chk1 abrogation and DNAdamaging treatment include apoptosis and premature mitotic entry (Table 1) . However, it is not clear if the cells with 4N DNA content (G2) have undergone permanent senescence or arrested temporarily until the removal of Chk1 inhibitors. If these cells are in 'premitotic catastrophe phase' would they enter mitosis or undergo later cell death without attempting mitosis? In the next section, we describe how the role of Chk1 in the DNA-damage cell cycle checkpoint and apoptosis may help us to understand this question. Furthermore, we believe that better understanding of how cells respond to cytotoxic treatments is required to gauge accurately the efficiency of combination treatments.
DNA damage induced apoptosis and role of Chk1
The general consensus that inhibition of Chk1 prevents degradation of Cdc25A leading to premature mitotic entry and sensitization to replication stress inducers has been recently challenged (Parsels et al., 2009) . It is proposed that although S or G2/M checkpoint bypass has a dominant role in mediating the sensitizing effects of Chk1 inhibitors, end points reflecting other molecular events might also reflect the effects of Chk1 antagonists on tumor response to chemotherapy in vivo (Parsels The role of Chk1 and other DNA-damage transducers in the regulation of cell death as an end point is also not well understood, especially in p53-independent pathways. Depletion of Chk1 using small interfering RNA potentiates response to DNA replication inhibitors and induces cell death during the S phase among cells that have lost p53 function (Cho et al., 2005; Rodriguez and Meuth, 2006) . Interestingly, apoptotic cell death is further induced in p21-deficient cells. Studies suggest that replication stress and Chk1 depletion activates p21 and prevents the S-phase apoptosis by inhibition of replication origin firing (Rodriguez and Meuth, 2006; Rodriguez et al., 2008) . As a p53 transcriptional target, p21 is classically proposed to be under the regulation of the ATM-p53 pathway where it induces G1 arrest. Modulation of p21 expression and consequent apoptosis can also occur via p53-independent pathways (Mahyar-Roemer and Roemer, 2001 ). In fact, p21 expression in pancreatic carcinoma is independent of p53 status (DiGiuseppe et al., 1995) . AliouatDenis et al. (2005) reported a p53-independent role for Chk2 in p21 induction and senescence. Moreover, the p38MAPK checkpoint pathway that regulates G2/M has recently been shown to regulate p21 function at the G1/S checkpoint in a p53-independent pathway (Lafarga et al., 2009 ). Considering the cross-talk between ATR and ATM pathways, and that replication stress and single-strand breaks may also lead to ATM activation (Ewald et al., 2007) , it appears likely that p21 activation via p53-dependent or -independent mechanisms may hinder apoptosis induced by Chk1 inhibitors.
Independently of ATM or p53 status, Chk1 depletion results in replication protein A foci accumulation, caspase-3 activation and apoptosis (Myers et al., 2009) . Sidi et al. (2008) reported that replication stress after DSB activates a different pathway where Chk1 suppresses a caspase-2-dependent apoptotic pathway. Chk1 inhibition hyperactivates ATM, ATR and caspase-2 after g-radiation and triggers a caspase-2-dependent apoptotic program that bypasses p53 deficiency and excess Bcl2 (Sidi et al., 2008) . In addition, caspasemediated cleavage of Chk1 during apoptosis leads to enhanced apoptotic reactions (Okita et al., 2007; Matsuura et al., 2008) . These data suggest a positive feedback role for Chk1 on apoptosis induction if cells encounter sufficient DNA damage to commit to apoptosis. Chk1 and Chk2 also affect the stabilization and activation of E2F1 and p73 after genotoxic stress. Chk1, Chk2, E2F1 and p73 were suggested to function in a pathway mediating p53-independent cell death induced by cytotoxic drugs (Urist et al., 2004) . Taken together, these observations suggest a role for Chk1 in coupling DDRs to downstream effector functions that not only activate the cycle checkpoint but also selectively controls apoptotic pathways.
Treatment-induced response pathways: apoptosis and beyond
Dissecting the complexity of the DDR network would not only assist with the assessment of end points such as cell death, cell cycle arrest and mitotic catastrophe but also modulation of responses to favor different effectors. Although abrogation of the G2/M cell cycle checkpoint in combination with DNA-damaging agents is a promising strategy for cancer treatment, in vitro and in vivo studies show that such combination treatments culminate in a range of end points. Although the clonogenic survival assay is a powerful tool to determine the collective cellular response, the resulting in vitro 'snapshot' does not satisfactorily represent the dynamics (Matthews et al., 2007) and CHIR-124 (Tse et al., 2007) ). Mitotic index was measured by p-H3 in cells. Cells in G2 were determined from cell cycle analysis performed after the removal of floating cells. Overall response comprises % cells in apoptosis, % in mitotic catastrophe (% p-H3 þ cells after abrogation of arrest) and % in G2 arrest (estimated from cell cycle analysis assuming that the cells analyzed total 100%, including % apoptotic and % p-H3 þ ).
a
The arrest was assumed to be all the remaining cells, as clonogenic survival assays showed very strong growth inhibition.
Targeting DDR pathways to improve cancer treatment F Al-Ejeh et al of tumor re-growth in animal models, as is consistently shown in pre-clinical studies. Long-term clonogenic assays in vitro, which show complete restoration of cell survival even after combination treatments, may provide an alternative explanation for tumor re-growth. Hence, we propose apoptotic or necrotic cell death rather than 'clonogenic death' or 'proliferative death' as the preferred end point for assessing the probability of tumor re-growth. Of therapeutic consequence, combining DNA repair and checkpoint inhibitors with apoptotic-pathway modulation might favor proapoptotic responses to DNA-damaging anticancer treatment as described in further detail below.
The dominant cancer treatment paradigm is that disruption of apoptotic responses in tumors owing to the presence of mutant p53 or increased levels of antiapoptotic proteins including Bcl2 and survivin increases resistance to anticancer therapeutics. Clinical studies have not definitively indicated that apoptosis is primarily responsible for tumor responses (Brown and Wouters, 1999; Brown and Wilson, 2003) . Although these clinical data are not in conflict with the recognized role that evasion of apoptosis has in tumorigenesis (Hanahan and Weinberg, 2000) , some pre-clinical data challenge the proposition that apoptosis is the only mediator of treatment response (Brown and Wouters, 2001) .
Clinical relevance of cell death pathways
Classically, necrosis and apoptosis are the two main cell death responses that differentiate non-programmed from programmed cell death, respectively. Programmed cell death pathways other than apoptosis-autophagic cell death and paraptosis-have also emerged with molecular and mechanistic classifications (Bredesen, 2008; Lockshin and Zakeri, 2008) . Although these classifications help our understanding of cell death pathways and suggest novel therapeutic targets, 'it will be far more interesting to learn how, in vivo, healthy and viable cells read signals and respond by committing to cell death' (Lockshin and Zakeri, 2008) . The Nomenclature Committee on Cell Death proposes that a cell should be considered dead when the cell has lost the integrity of its plasma membrane (incorporation of vital dyes) (Kroemer et al., 2009) . Strikingly, however, direct measurement of the common end point of cell death that is the 'breach of plasma membrane integrity' is lacking not only in clinical studies but also in pre-clinical models. In addition, cellular responses such as therapyinduced senescence and mitotic catastrophe (Figure 2 ) are now recognized for their contribution to the overall loss of tumor cell viability (de Bruin and Medema, 2008; Singh et al., 2010) . These phenomena reinforce the need to determine the overall contribution that cell death makes in comparison with other cellular response pathways.
Senescence. Like apoptosis, senescence has been proposed as a tumor suppressor mechanism (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Lazzerini Denchi et al., 2005; Michaloglou et al., 2005) . In normal cells, genotoxic and oncogenic stress activate the p53-p21 and p16-pRB pathways, respectively, leading to transient or permanent growth arrest. Deregulation of these pathways in tumors presumably provide cells with a survival advantage in escaping senescence (Campisi, 2008 Figure 2 Cell death after anticancer drugs and DDR inhibitors. The DDR pathway is activated after treatment to promote survival. Downstream effectors of cell death pathways are activated when DNA damage extends beyond repair and/or occur under the influence of DNA repair and cell cycle checkpoint inhibitors to initiate various responses. These responses include necrosis, apoptosis, mitotic catastrophe and senescence. When the apoptotic machinery is disabled, for example, by mutant p53 (dashed gray line), mitotic catastrophe and senescence may be favored as responses. Cells in mitotic catastrophe may subsequently undergo micronucleation, senescence, apoptosis or necrosis. Senescent cells are alive and may not only promote tumor growth but may also reverse their state and survive anticancer treatment. Micronucleated cells produced after aberrant mitosis or senescence have been suggested to survive by a process termed 'neosis'. Neosis is a parasexual, somatic, reduction division displayed by a subset of multinucleate and/or polyploid giant cells formed after genotoxic stress-induced accelerated senescence or mitotic catastrophe in tumor cells. It is characterized by chromosome distribution to daughter cells by nuclear budding in the presence of an intact nuclear envelope, followed by asymmetric cytokinesis, giving rise to an indefinite number of small, aneuploid, mitotically active cells termed Raju cells (Rajaraman et al., 2006) . As proposed by the Nomenclature Committee on Cell Death, bona fide 'dead cells' (apoptotic and necrotic) are different from 'dying cells' (in mitotic catastrophe or senescence) that ' have not yet concluded their demise' (Kroemer et al., 2009 ).
Targeting DDR pathways to improve cancer treatment F Al-Ejeh et al a wild-type p53 or p16 model of Burkitt's lymphoma revealed that responses to cyclophosphamide correlated with increases in the senescence-associated marker bgalactosidase (SA-b-gal) that is lost when p53 or p16 mutations were introduced (Schmitt et al., 2002) . Tissuespecific increases of SA-b-gal were associated with low p53 staining and high p16 staining in patients receiving induction chemotherapy for breast cancer (te Poele et al., 2002) . High-level SA-b-gal staining was observed in tumors from non-small-cell lung cancer patients who received neoadjuvant chemotherapy compared with untreated patients or normal lung tissues (Roberson et al., 2005) . Although these findings collectively suggest that therapy-induced senescence is a mechanism of DNA DDR that occurs in vivo, cells that have undergone senescence can re-enter cell cycle by overexpression of the cyclin-dependent kinase Cdc2/Cdk1 (Roberson et al., 2005) . The Nomenclature Committee on Cell Death recommends that cells in the cell cycle arrest and senescence should be considered as alive (Kroemer et al., 2009 ).
Mitotic catastrophe. Mitotic catastrophe is an abnormal mitosis that is characterized by micronucleated cells that continue with mitosis to form aneuploid cells, abort mitosis and die apoptotic or necrotic deaths, or undergo irreversible growth arrest. Thus, the term mitotic catastrophe should be restricted to faulty mitosis leading to irreversible growth arrest or cell death (by apoptosis or necrosis) (Vakifahmetoglu et al., 2008b; Kroemer et al., 2009; Portugal et al., 2009 Portugal et al., , 2010 .
Mitotic catastrophe (MC) has been reported as a prominent response to different anticancer drugs that affect cytoskeletal components and include microtubule toxins (Tounekti et al., 1993; Lock and Stribinskiene, 1996; Torres and Horwitz, 1998; Taylor et al., 2006) , radiotherapy (Streffer et al., 1986; Falkvoll, 1990; Zolzer et al., 1995; Bhattathiri et al., 1998; Widel et al., 1999) and chemotherapy (Yashige et al., 1999) . Cell cycle checkpoint inhibitors in combination with DNA-damaging agents enhance MC by inducing 'mitotic slippage'. A recent study has used automated time-lapsed video microscopy to provide insights into the fate of individual cells entering catastrophic mitotic arrest after antimitotic drug treatment (Gascoigne and Taylor, 2008) . A panel of cell lines treated with several antimitotic drugs displayed significant inter-as well as intra-cell line differences in cellular responses, including death by apoptosis during mitosis (that is, 'mitotic death'), or death post-mitosis in cells that slipped into interphase (that is, exit mitotic arrest) (Gascoigne and Taylor, 2008) . Importantly, the variation in daughtercell responses to the division of a single parent cell after antimitotic drug challenge illustrates that intra-cell line variation is not owing to a genetic predisposition. Overall, the study suggested that independent but competing processes involving cell death or mitotic exit signals determine the fate of cells after antimitotic challenge. Cells, which breach a threshold of cell death signaling, die during mitotic arrest, whereas cells, which breach a mitosis exit threshold by cyclin B1 degradation, enter interphase. These post-mitotic cells may subsequently vary in their responses, which include cell death, prolonged arrest or abnormal cell divisions, possibly guided by similar signaling thresholds (Gascoigne and Taylor, 2008) .
Therapy-induced senescence, mitotic arrest and cell death: paradox or seesaw? A frequently asked question in the area of cancer therapy is 'which response pathway is indicative of favorable treatment outcome?' As described above, there have been attempts to identify apoptosis, senescence or mitotic catastrophe as proximate causes of tumor responses to anticancer treatment. Surprisingly, to our knowledge, these response pathways have not been investigated concurrently in a single pre-clinical or clinical study that would correlate these end points with tumor response or overall survival. It has been suggested that apoptosis is an insufficient measure of the response of tumors to therapy (Brown and Wouters, 1999; Brown and Wilson, 2003) . Our current understanding points to significant cross-talk among different response pathways. Analyses of cells harboring faults in p21 and p53 within different cellular models of anticancer treatment suggest varied outcomes that depend on the initiating response pathway. In response to cytotoxic drugs, tumor cells may display characteristics of senescence or autophagy by delaying apoptosis at early time points of cytotoxic stress or, at higher toxic doses, tumor cells may display characteristics of apoptosis and, at later time points, of repressed senescence (Chang et al., 1999) . Moreover, each type of cellular response results in a very different clonogenic potential. Although such information may appear conflicting, viewing cellular responses as an orchestrated interplay of various competing pathways (Gascoigne and Taylor, 2008 ) may alter our perspectives on tumor responses to anticancer treatments.
Although the genetic divergence of cancer cells from normal cells may reset the threshold for activation of various cellular survival and death pathways, it does not necessarily predetermine cellular fate after genotoxic or non-genotoxic insults (Figure 3) . Rather, the response of a given tumor cell type to such insults is determined by the interplay between many different normal and defective, or hyperactivated and suppressed, signaling pathways. The assumption that a single response pathway may determine a treatment outcome is challenged by the presence of ill-understood feedback mechanisms. For example, although senescent cells do not divide, these cells are not eliminated by the immune system. In addition to the possibility of its reversal (for example, by escape by Cdc2/Cdk1 overexpression; Roberson et al. (2005) ), senescence is also associated with a secretory phenotype (for example, of mitogenic and antiapoptotic factors) that could promote tumor progression (Roninson et al., 2001) . Hence, 'senescence should not be viewed as merely an end point in a cell's life cycle, but rather as a physiological state determined by the homeostatic programs of a multicellular organism' (Roninson and Broude, 2008) .
Targeting DDR pathways to improve cancer treatment F Al-Ejeh et al
Restoring apoptosis in cancer in response to treatments
As reviewed above, DNA damage may induce different cellular responses, including growth delay, reversible arrest, permanent arrest (senescence) or apoptosis. Abrogation of DNA-damage signal transduction or repair may promote these outcomes. Treatment strategies that incorporate DNA damage with inhibition of its repair also have a greater potential of inducing mitotic entry of cells with damaged DNA leading to mitotic catastrophe and eventually cell death. Variability in the types of cellular response to treatment-induced DNA damage helps to explain the persisting debate concerning which mechanisms best describe therapeutic drug responses in vivo (Roninson et al., 2001; Roninson, 2002) . Several reports, which describe cross-talk between death effector mechanisms, suggest that therapeutic strategies that include DDR-pathway inhibition should also target downstream effectors as a way to ultimately divert cellular responses toward an apoptotic or necrotic cell death. One interesting example is the proposed regulation of the final mode of cell death triggered by DNA damage in ovarian carcinoma cells. Vakifahmetoglu et al. (2008a) reported that molecular profiles involving caspase-2, Chk2 as well as p53 not only determine whether cells undergo cell cycle regulation, necrosis, apoptosis or mitotic catastrophe but also determine whether cells undergo apoptosis or necrosis following mitotic catastrophe. More effective therapy for refractory malignancies has been investigated using small-molecule inhibitors to target key proteins in the intrinsic apoptotic pathway (Goldsmith et al., 2006; Gudiksen et al., 2008) . Exploiting the endogenous cell death machinery to reactivate the apoptotic cell death pathway may be achieved by antagonizing prosurvival Bcl2 family members directly or by inhibiting apoptosis downstream of Bcl2 induction. Modulation of Bcl2 family members using small-molecule drugs in tumor cells, which may carry one or more such dysregulated signaling pathways, may present an effective way to sensitize tumor cells to combination therapies (Labi et al., 2006; Walensky, 2006; Zinkel et al., 2006; Reed, 2006b) . Small-molecule inhibitors targeting Bcl2 family proteins such as the BH3-only peptidomimetic drugs (for example, ABT-737) are under evaluation in pre-clinical and clinical trials with the promise of single-agent activity against numerous cancers (Adams and Cory, 2007; Zhang et al., 2007; Cragg et al., 2009) .
The convergence of apoptotic signaling on the caspases makes these proteases the ultimate effectors of cell death (LaCasse et al., 2008) . Nevertheless, to Figure 3 Therapy-induced cellular responses: paradox or seesaw. The genetic divergence of cancer cells from normal cells resets the threshold for the activation of various survival and death pathways. Elevation of the response threshold (for example, by overexpression of drug resistance mechanisms or upregulation of autophagy) may desensitize cells to low or normal doses of cytotoxic stressors. At higher doses of cytotoxic stressors or in the absence of a response threshold elevation, the response of a given cell may be determined by the resulting interplay between many different normal and defective, or hyperactivated and suppressed, signaling pathways. Where the cell death threshold is normal (a), cells may undergo cell death or temporary cell cycle arrest depending on p53 status and expression of p21 and p16. Conversely, where the cell death threshold is elevated (b), and in the presence of mutated p53 or the upregulation of pro-survival proteins such as Bcl2, cells may turn to responses other than cell death. Cells in temporary cell cycle arrest may undergo permanent cell cycle arrest (senescence) or cell death depending on the interplay between p21-p16-and p53-independent cell death pathways.
Targeting DDR pathways to improve cancer treatment F Al-Ejeh et al avoid unwarranted cell death, tight regulation of caspase activation is mediated physiologically by inhibitors of apoptosis (IAPs). The observation that elevation of the IAP survivin in cancers correlates with poor prognosis led to the hypothesis that IAP overexpression might be an oncogenic event and thus a potential target for the therapeutic induction of apoptosis in tumors (Altieri, 2003; Duffy et al., 2007; LaCasse et al., 2008) . IAP inhibitors have the advantage of permitting direct reactivation of the caspase cascade independently of any blocks in the apoptotic pathway upstream of the mitochondria, such as overexpression of prosurvival Bcl2 or mutation of Bax and/or Bak (LaCasse et al., 2008) . Currently, several synthetic chemicals that inhibit IAPs are in pre-clinical evaluation (Reed, 2006a; Hunter et al., 2007) .
Assessment of therapy-induced responses in animal models
Although our understanding of the signaling and crosstalk mechanisms responsible for the phenomena of cell growth, survival, death and proliferation advances rapidly, it also poses new challenges for the development of in vivo assessment methods of matching accuracy (Kim, 2005; Maddika et al., 2007; Eisenberg-Lerner et al., 2009) . In addition to measurements of cell death (Al-Ejeh et al., 2007 , 2009 Cohen et al., 2007; Kartachova et al., 2007) , proliferation and senescence (SA-b-gal staining) can also be measured by noninvasive real-time live imaging. As indices of tumor cell viability and proliferation, measurement of tumor cell incorporation of 18-fluorodeoxyglucose and 18-fluoro-L-thymidine, respectively, by positron emission tomography can be used to assess tumor responses. Nevertheless, it is important to consider some of the limitations of these imaging methods in the evaluation of biological responses to anticancer treatments. For example, 18-fluorodeoxyglucose-L-thymidine uptake may be falsely low if drug effects are reversible or falsely high if macrophages partake in the healing response to tumor cell death. Similarly, 18-fluoro-L-thymidine uptake may be falsely low if cell cycle arrest is reversible. However, combining these imaging agents with other methods such as measurement SA-b-gal activity (Tung et al., 2004; Liu et al., 2007) and cell death (Al-Ejeh et al., 2007 , 2009 Thierry et al., 2009) can be used to monitor accurately the status of tumors, for example, in response to DNAdamaging chemotherapy. 'Certainly, mouse models of cancer have been used to address genetics of tumorigenesis for years, but they have been understudied as experimental platforms to investigate short-and long-term consequences of druginducible effector programs' (Kilic and Schmitt, 2008) . Transgenic mouse models may easily be adapted to investigate the therapeutic efficacy of novel DDRpathway inhibitors in combination with other anticancer treatments. In addition to observational studies of tumor growth or survival, other studies of interest include detailed genetic and biochemical analyses of drug-induced effector pathways and treatment response susceptibilities. These studies may be combined with real-time imaging studies that seek to dissect the relative contributions of cell death and proliferation to overall treatment outcomes.
Concluding remarks
The DDR pathways include several targets for molecular inhibitors to potentiate DNA-damaging anticancer treatments. Combinations of DDR inhibitors and DNA-damaging agents are currently under clinical evaluation in advanced cancer patients. Multiple treatment response outcomes, such as cell death, cell cycle arrest, mitotic catastrophe and senescence, are observed in vitro and in pre-clinical models using DDR inhibitors and DNA-damaging agents. Pharmacological modulations that enhance cell death responses are likely to improve the efficacy of DNA-damaging agents when used in combination with DNA repair and/or cell cycle checkpoint inhibitors. Clearly, the characterization of new targets that restore cell death pathways together with an increased understanding of the mechanistic coupling DDR to the intrinsic apoptotic pathway would help us to guide the response to DNA damage from upstream sensors to downstream proapoptotic responses.
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